| Literature DB >> 34976758 |
Yuanyuan Qi1, Libo Wang1, Liling Qian1, Xiaobo Zhang1.
Abstract
BACKGROUND: Diffuse alveolar hemorrhage (DAH) is a life-threatening syndrome that may be caused by numerous disorders. There is scant data on the etiology and characteristics of DAH in children.Entities:
Keywords: Diffuse alveolar hemorrhage; bronchial artery embolization; etiology; idiopathic pulmonary hemosiderosis
Year: 2021 PMID: 34976758 PMCID: PMC8649607 DOI: 10.21037/tp-21-283
Source DB: PubMed Journal: Transl Pediatr ISSN: 2224-4336
Underlying etiology of DAH
| Etiology | Number (%) |
|---|---|
| Idiopathic pulmonary hemosiderosis (IPH) | 48 (64.9) |
| Miscellaneous causes | 12 (16.2) |
| Sepsis | 6 |
| Pneumonia-induced acute respiratory distress syndrome (ARDS) | 3 |
| Enterovirus A71 (EV71) infection | 1 |
| Influenza B infection | 1 |
| Drowning | 1 |
| Immune-mediated disorders | 7 (9.5) |
| Anti-neutrophil cytoplasmic antibody (ANCA) associated granulomatous vasculitis | 3 |
| Goodpasture syndrome | 3 |
| Evans syndrome | 1 |
| Liver dysfunction | 4 (5.4) |
| Acute liver failure | 3 |
| Favism | 1 |
| Cardiovascular disorders | 3 (4.1) |
| Heart failure | 2 |
| Vascular malformation | 1 |
Patient characteristics and outcome according to the etiology
| Variables | All patients (n=74) | Immune related (n=7) | Liver dysfunction (n=4) | Cardiovascular causes (n=3) | Miscellaneous (infection and other conditions) (n=12) | IPH (n=48) | P value |
|---|---|---|---|---|---|---|---|
| Age, year | 3.5 (1.5–7) | 9 (6.0–11.0) | 0.15 (0.1–0.425) | 13 (0.6–13) | 1.5 (0.7–5.5) | 4.0 (2–6.8) | 0.001 |
| Male gender, % | 38 (51.4) | 4 (57.1) | 4 (100.0) | 3 (100.0) | 4 (33.3) | 23 (47.9) | 0.078 |
| Course, month | 1 (0.3–12.3) | 1 (1–6) | 0.7 (0.325–4.75) | 0.1 (0.075–0.55) | 0.25 (0.1–3) | 4.0 (1.0–16) | 0.006 |
| Presenting symptoms | |||||||
| Fever | 29 (39.2) | 2 (28.6) | 2 (50.0) | 1 (33.3) | 8 (66.7) | 16 (33.3) | 0.288 |
| Cough | 45 (60.8) | 3 (42.9) | 0 (0) | 1 (33.3) | 3 (25.0) | 38 (79.2) | <0.001 |
| Anemia | 62 (83.8) | 7 (100.0) | 3 (75.0) | 0 (0) | 7 (58.3) | 45 (93.8) | <0.001 |
| Hemoptysis | 48 (64.9) | 4 (57.1) | 1 (25.0) | 3 (100.0) | 9 (75) | 31 (64.6) | 0.280 |
| Dyspnea | 33 (44.6) | 3 (42.9) | 3 (75.0) | 3 (100.0) | 11 (91.7) | 12 (25.0) | <0.001 |
| Hypoxia | 32 (43.2) | 4 (57.1) | 4 (100.0) | 2 (66.7) | 11 (91.7) | 11 (22.9) | <0.001 |
| Clubbing | 2 (2.7) | 0 (0) | 0 (0) | 1 (33.3) | 0 (0) | 1 (2.1) | 0.024 |
| Crackles | 20 (27.0) | 0 (0) | 0 (0) | 1 (33.3) | 6 (50.0) | 13 (27.1) | 0.123 |
| Hb, g/L | 76.8±32 | 67.3±22.6 | 82.8±15.2 | 159±64.9 | 94.4±30.1 | 68.1±22.6 | 0.002 |
| Pulmonary infiltrates | 66 (89.2) | 7 (100.0) | 3 (75.0) | 3 (100.0) | 9 (75.0) | 44 (91.7) | 0.309 |
| DAH classical triad* | 36 (48.6) | 4 (57.1) | 1 (25.0) | 0 (0) | 4 (33.3) | 27 (56.3) | 0.192 |
*, refers to hemoptysis, anemia and pulmonary infiltrates on chest imaging.
Treatment, hospital duration and outcome
| Variables | All patients (n=74) | Immune-mediated (n=7) | Liver dysfunction (n=4) | Cardiovascular causes (n=3) | Miscellaneous (infection and other conditions) (n=12) | IPH (n=48) | P value |
|---|---|---|---|---|---|---|---|
| Blood transfusion | 53 (71.6) | 6 (85.7) | 4 (100.0) | 1 (33.3) | 7 (58.3) | 35 (72.9) | 0.280 |
| IVIG | 23 (31.1) | 4 (66.7) | 2 (50.0) | 1 (33.3) | 6 (50.0) | 9 (18.8) | 0.013 |
| Oxygen treatment | 38 (51.4) | 6 (85.7) | 4 (100.0) | 2 (66.7) | 11 (91.7) | 15 (31.3) | <0.001 |
| Mechanical ventilation | 25 (33.8) | 4 (66.7) | 3 (60.0) | 2 (66.7) | 10 (83.3) | 6 (12.5) | <0.001 |
| Hospital length of stay, days | 13±1.5 | 14.3±12.7 | 3.8±2.2 | 12.3±2.5 | 19.7±21.7 | 11.9±9.7 | 0.145 |
| In hospital mortality | 19 (25.7) | 3 (42.9) | 4 (100.0) | 2 (66.7) | 9 (75.0) | 1 (2.1) | <0.001 |
Demographic characteristics and prognosis in BAE and non-BAE patients
| Variables | BAE (n=31) | Non-BAE (n=17) | P value |
|---|---|---|---|
| Age at diagnosis, years | 5.2±4.0 | 4.0±3.2 | 0.311 |
| Male gender, % | 11 (35.5) | 12 (70.6) | 0.034 |
| Disease course, months | 20.1±31.2 | 17.7±37.1 | 0.812 |
| Hb >120 g/L, % | 21 (67.7) | 14 (82.4) | 0.330 |
| Duration of corticosteroids, months | 5.5 [3–10] | 10 [8–15] | 0.020 |
| Relapse, % | 11 (35.5) | 12 (70.6) | 0.021 |
| Frequency of relapses | 0 [0–1] | 2 [0–2] | <0.001 |